iPro Realty Ltd. shut down by Ontario's real estate watchdog
A Toronto-area real estate brokerage is no more after the province's industry watchdog said that it discovered a 'significant shortfall' in its accounts.
The Real Estate Council of Ontario (RECO) says it has finalized an undertaking with Mississauga-based iPro Realty Ltd. which will lead to the brokerage's wind-up and closure as of Aug. 19.
'This is a serious breach of iPro's responsibilities under the law and to its consumers and agents,' RECO said of the shortfall.
RECO did not disclose the value of the deficit.
There are 2,400 agents employed at iPro and the brokerage has locations in Mississauga, Toronto, North York, Scarborough, and across the Greater Toronto Area.
RECO will oversee operations at iPro until it closes on Aug. 19.
I sold my property with iPro. Will my deal close?
According to RECO, transactions involving iPro will continue to close in the normal course of business.
'First and foremost, please contact the real estate agent you have been working with. If you need more assistance than your agent is able to provide, ask to speak to the management of iPro,' RECO wrote in a news release.
RECO said it, the new leadership of iPro, and the insurer are working to minimize the impact on consumer deposits.
Those owed a commission by iPro can file an insurance claim, however the limit per individual claimant is $200,000 and the insurance payouts related to this event will be capped at $4 million.
I'm selling my property with iPro and have offers on the table. What happens now?
RECO said that if your negotiations conclude before Aug. 19, the transaction will proceed, as long as you have a signed agreement of purchase and sale (APS).
'If the agreement to buy or sell a property has not been signed by all parties, you will have to sign a new representation agreement with your agent and their new brokerage,' it said.
If my deposit was held by iPro, where is it now?
RECO says that your APS should identify where your deposit is being held. If it is being held with iPro, RECO recommends reaching out the real estate agent you've been working with for more assistance.
My agent works at iPro. Can I still work with them?
RECO said many agents from iPro will be transferring to a new brokerage and you can sign a new representation agreement with them at their new brokerage. Alternatively, buyers and sellers can choose to sign a new representation agreement with a new agent if they choose.
CTV News Toronto has reached out to iPro and RECO for comment on the situation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
15 minutes ago
- Globe and Mail
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK , Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000 . Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000 . The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025 , and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025 , in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
CBC
16 minutes ago
- CBC
Burnaby company pitches plan to heat Kits Pool with bitcoin mining
A Burnaby company is proposing to heat Kitsilano Pool with excess heat from bitcoin mining. A UBC professor says the plan is energy inefficient, bad for Kits Pool, and bitcoin is a "slow-burning Ponzi scheme" with "no other use than to facilitate fraud, scams, and money laundering."
CBC
32 minutes ago
- CBC
Stellantis lays off 'small number' of workers in Windsor as company cuts back on EV muscle car
Stellantis is laying off workers at its assembly plant in Windsor, Ont., as the company shifts away from its electric muscle car. "A small number" of workers received layoff notices Friday, according to Stellantis spokesperson LouAnn Gosselin. "The layoffs are based on seniority and are a result of regular volume adjustments at the plant," Gosselin said. The company would not confirm the number of impacted employees. The union representing the plant's workers did not respond to a request for comment. The news comes on the last day of work before the plant's regular summer shutdown. It also comes at a time of heightened anxiety for auto workers in Canada, especially those in Windsor, where the economy relies heavily on the industry. Workers optimistic Employees at the Windsor assembly plant have faced temporary layoffs in recent months as a result of U.S. President Donald Trump's trade war with Canada and levies on the auto sector — though carve-outs for products that comply with CUSMA, the countries' existing trade deal, have softened the blow. The handful of workers who spoke to CBC Friday outside the Windsor assembly plant said they expect workers to be back on the job before long. "Could be a couple weeks," Emanuele Caruana said. "Right now things aren't looking too good, but they're going to be good soon." Dixon Bell described the layoffs as "not good" but said he too believed workers would be brought back eventually. Dave Lumley isn't worried at all, he said, and predicted the workers would be back on the job before Christmas. "It's just temporary," he said. "It's just a small amount. That happens a lot. It comes and goes. It's only 100 people." Lumley attributed the layoffs to changes in Dodge Charger production at the plant. "We have a battery area, and … we're not building batteries," he said. "Everybody wants gas, so they're trying to transition. That's mainly what it is." In May, Stellantis announced that it was postponing production of the Dodge Charger Daytona R/T, the base model of the first-of-their-kind electrified muscle cars, just a year after introducing them with great fanfare. The global automaker has blamed U.S. tariffs for the decision, but the move also followed weak sales amid a dampening EV market. Workers at the Windsor plant assemble both the Chargers and the company's minivan offerings, including the Chrysler Pacifica. Last week, Stellantis unveiled the 2026 Dodge Charger Scat Pack, equipped with an inline-six twin turbo engine, after months of pleading from gear heads to bring back gas-powered versions of the previously popular muscle cars.
